

American College of Radiology ACR Appropriateness Criteria®

Clinical Condition: Soft Tissue Masses

Variant 1: First study to order.

Radiologic Procedure	Rating	Comments	RRL*
X-ray area of interest	9	Necessary. Bone and soft tissue features assist in selecting second study.	NS
CT area of interest	1	Not first study.	NS
US area of interest	1	Not first study.	None
NUC bone scan targeted	1	Not first study.	Med
X-ray arthrography area of interest	1	Invasive, only useful for communicating cyst.	NS
MRI area of interest	1	Not indicated as first study, most often second study.	None
Rating Scale: 1=Least appropriate, 9=Most appropriate			*Relative Radiation Level

Variant 2: Radiograph negative.

Radiologic Procedure	Rating	Comments	RRL*
MRI area of interest without contrast	9	Start without contrast. If mass indeterminate for malignancy, use contrast.	None
MRI area of interest without and with contrast	9	Start without contrast. If mass indeterminate for malignancy, use contrast.	None
US area of interest	7	With proper expertise, may be appropriate.	None
CT area of interest with contrast	4	May be useful if MRI is contraindicated.	NS
NUC bone scan targeted	1		Med
CT area of interest without contrast	1		NS
Rating Scale: 1=Least appropriate, 9=Most appropriate			*Relative Radiation Level

An ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

Clinical Condition:**Soft Tissue Masses****Variant 3:****Radiograph calcified soft tissue mass.**

Radiologic Procedure	Rating	Comments	RRL*
MRI area of interest without contrast	9	If not demonstrated by CT to be myositis ossificans.	None
CT area of interest without contrast	9	If myositis ossificans is suspected.	NS
MRI area of interest without and with contrast	9	If not demonstrated by CT to be myositis ossificans.	None
CT area of interest with contrast	4	If not myositis ossificans and MRI contraindicated.	NS
NUC bone scan targeted	1		Med
US area of interest	1		None
Rating Scale: 1=Least appropriate, 9=Most appropriate			*Relative Radiation Level

Variant 4:**Superficial or near joint with or without radiographic abnormalities.**

Radiologic Procedure	Rating	Comments	RRL*
MRI area of interest without contrast	9	Start without contrast. If mass indeterminate for malignancy, use contrast.	None
MRI area of interest without and with contrast	9	Start without contrast. If mass indeterminate for malignancy, use contrast.	None
US area of interest	7	With proper expertise, could substitute for MRI. Especially if ganglion is suspected, particularly in the wrist.	None
CT area of interest with contrast	4	May be useful if MRI is contraindicated.	NS
NUC bone scan targeted	1		Med
X-ray arthrography area of interest	1		NS
CT area of interest without contrast	1		NS
Rating Scale: 1=Least appropriate, 9=Most appropriate			*Relative Radiation Level

An ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

Clinical Condition:**Soft Tissue Masses****Variant 5:****Abdominal or chest wall.**

Radiologic Procedure	Rating	Comments	<u>RRL*</u>
CT area of interest with contrast	9		NS
X-ray area of interest	9	Localization, calcification, etc., important for selecting additional studies.	NS
MRI area of interest without contrast	7	May be limited due to motion artifact.	None
MRI area of interest without and with contrast	7	May be limited due to motion artifact.	None
NUC bone scan targeted	4	If expertise available. Depends on the specific question to be answered.	Med
CT area of interest without contrast	4	May be indicated in specific situations such as hernia.	NS
US area of interest	1		None
<u>Rating Scale:</u> 1=Least appropriate, 9=Most appropriate			*Relative Radiation Level

An ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

SOFT TISSUE MASSES

Expert Panel on Musculoskeletal Imaging: William B. Morrison, MD¹; Murray K. Dalinka, MD²; Richard H. Daffner, MD³; Arthur A. De Smet, MD⁴; George Y. El-Khoury, MD⁵; John B. Kneeland, MD⁶; B.J. Manaster, MD, PhD⁷; Helene Pavlov, MD⁸; David A. Rubin, MD⁹; Robert Schneider, MD¹⁰; Lynne S. Steinbach, MD¹¹; Barbara N. Weissman, MD¹²; Robert H. Haralson III, MD.¹³

Summary of Literature Review

Imaging techniques for patients with suspected soft tissue masses may be requested because of a painful or painless soft tissue abnormality palpated by the patient or physician or because of symptoms such as pain or other complaints with no detectable mass on physical examination. The type of imaging technique initially selected varies depending on the history and physical findings as well as the suspected location of the lesion. It is well known that biopsy of a presumed soft tissue mass without an imaging work-up is inadvisable for a number of reasons.

There has been tremendous progress in imaging evaluation of soft tissue masses over the years. Routine radiographs still play an important role in identifying certain features that may either allow the diagnosis to be established or indicate which procedure might be most appropriate for further evaluation. Computed tomography (CT) and ultrasound (US) greatly improve the ability to detect and, in some cases, characterize the nature of soft tissue masses. With the advent of magnetic resonance imaging (MRI), lesion detection, differentiation of normal anatomic variants from true lesions, and characterization of lesions has improved because of its superior soft tissue contrast and multiple-image plane capabilities [1-4].

Routine radiography is an important first technique for evaluating patients with suspected soft tissue abnormality, especially those that are deep and nonpalpable. Certain features on the routine radiograph may provide valuable insight into the most appropriate additional studies that may be required. For example, well-defined lucency in the soft tissues may indicate a

lipoma that could be evaluated with either CT or MRI. Patients with subtle bone change or soft tissue calcification may be more appropriately studied with CT, because lesion characterization may be improved with this imaging technique [4-6]. Also, lesions arising from bone (ie, osteochondroma or soft tissue component of a bone tumor) can present as deep soft tissue masses clinically.

US is not frequently used for evaluating soft tissue masses at most institutions. This technique is valuable in differentiating cystic from solid lesions and has also been used to study vascularity of lesions [5,7,8]. For soft tissue prominence at a joint, US may offer a specific diagnosis (eg, ganglion cyst, paralabral or parameniscal cyst). However, US is not as useful for characterizing pathology or defining the extent of true soft tissue masses [9].

Since the introduction of MRI, CT has largely been replaced as the technique of choice for evaluating soft tissue masses. However, in some cases, CT may still be appropriate for evaluating soft tissue lesions. Situations such as suspected lipoma, calcification in soft tissue lesions seen on routine radiographs, or suspected myositis ossificans based on clinical or radiographic data might be better evaluated with CT. Lipomas are easily characterized on both CT and MRI [4,6]. In addition, patient size or location of lesion may dictate that CT would be the preferred technique. Such locations include the abdominal or chest wall, where motion artifact can create suboptimal imaging with MRI [4,10]. A report of the Radiology Diagnostic Oncology Group on 133 soft tissue tumors suggested that MRI and contrast-enhanced CT are comparable with reference to determining tumor size and involvement of surrounding structures [11].

MRI has become the technique of choice for detecting and characterizing soft tissue masses. Its improved soft tissue contrast and multiple-image plane capabilities have provided significant advantages for lesion conspicuity, characterization, and determining the extent of involvement [2-4,10,12-14]. Vascular structures can also be more easily identified and evaluated without the need for intravenous contrast agents [4]. Vascular structures and neurovascular involvement are more easily defined in 20% of cases compared with CT [4]. Cortical bone involvement by soft tissue masses can be identified equally by both CT and MRI [2,4,10,11]. However, the extent of marrow involvement can be difficult to determine by CT, and there is evidence that tumor infiltration can extend beyond the apparent margin of the mass [15].

¹Thomas Jefferson University Hospital, Philadelphia, Pa; ² Panel Chair, University of Pennsylvania Hospital, Philadelphia, Pa; ³Allegheny General Hospital, Pittsburgh, Pa; ⁴University of Wisconsin, Madison, Wis; ⁵University of Iowa Hospitals and Clinics, Iowa City, Iowa; ⁶University of Pennsylvania Hospital, Philadelphia, Pa; ⁷University of Colorado Health Science Center, Denver, Colo; ⁸Hospital for Special Surgery, New York, NY; ⁹Washington University of St. Louis, St. Louis, Mo; ¹⁰Hospital for Special Surgery, New York, NY; ¹¹University of California, San Francisco, Calif; ¹²Brigham & Women's Hospital, Boston, Mass; ¹³American Academy of Orthopaedic Surgeons, Chicago, Ill.

Reprint requests to: Department of Quality & Safety, American College of Radiology, 1891 Preston White Drive, Reston, VA 20191-4397.

An ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

Though lesions are more easily detected with MRI, its ability to differentiate benign from malignant lesions remains controversial. Numerous studies have evaluated MR imaging features of soft tissue lesions [1,11,14-23]. Reports discussing correct histologic diagnosis or differentiating benign from malignant lesions describe accuracy ranges from 24%-90%. Though imperfect, the superior soft tissue contrast provided by T2-weighted MR images provides features that are useful for characterizing lesions. Malignant lesions are heterogeneous (72%-94%), larger (90% > 33 mm), and more frequently involve bone and neurovascular structures [2,10,14]. The pattern of gadolinium enhancement may help identify some lesions as malignant, such as myxoid liposarcoma, and has shown utility in evaluating aggressiveness of vascular and lipomatous masses [18,19].

Contrast is useful for identifying cystic and necrotic components of soft tissue masses, helping to characterize lesions and identifying solid areas for biopsy. Dynamic gadolinium enhancement characteristics may be useful, but there is overlap between benign and malignant lesions [20,21]. Advanced MRI techniques such as spectroscopy and diffusion-weighted imaging have potential for differentiating benign from malignant lesions but need more refinement [6,22-24]. Even when MRI cannot characterize the type of lesion, it remains very useful for percutaneous biopsy and surgical planning.

Radionuclide studies are not indicated in most situations for evaluation of soft tissue masses. Techniques such as PET scanning have been used mainly for evaluating metastatic disease and follow-up of treated lesions.

Arthrography or invasive techniques are also rarely indicated, if at all, for evaluating soft tissue masses. Popliteal cysts or communicating cystic lesions can be identified by introducing contrast material into the joints. However, this is not a well accepted and is rarely performed today. With few exceptions, such as AV malformations or hemangiomas, angiography is also not frequently performed for the detection or staging of soft tissue lesions [5].

Anticipated Exceptions

As a general rule, MRI is the technique of choice for evaluating patients with suspected soft tissue masses [2,10,12,14]. There are some exceptions where other techniques may be of equal or greater value. CT may be of greater value in patients who demonstrate subtle cortical bone involvement or soft tissue calcifications on routine radiographs. Patient size, patients with certain metallic or electrical implants, claustrophobic patients, and patients who are unable to remain motionless (because of pain, Parkinson's disease, etc.) for the

length of an MRI examination may have to be studied with an alternate technique. CT would be selected in most situations.

Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria® [Radiation Dose Assessment Introduction](#) document.

Relative Radiation Level Designations	
Relative Radiation Level*	Effective Dose Estimate Range
None	0
Minimal	< 0.1 mSv
Low	0.1-1 mSv
Medium	1-10 mSv
High	10-100 mSv

*RRL assignments are not included for some examinations. The RRL assignments for the NS (not specified) exams cannot be made because the RRL depends on the region of the body exposed to ionizing radiation, and the body part will vary as a function of the clinical situation.

References

1. Binkovitz LA, Berquist TH, McLeod RA. Masses of the hand and wrist: detection and characterization with MR imaging. *AJR* 1990; 154(2):323-326.
2. Weekes RG, Berquist TH, McLeod RA, Zimmer WD. Magnetic resonance imaging of soft-tissue tumors: comparison with computed tomography. *Magn Reson Imaging* 1985; 3(4):345-352.
3. Vanel D, Shapeero LG, De Baere T, et al. MR imaging in the follow-up of malignant and aggressive soft-tissue tumors: results of 511 examinations. *Radiology* 1994; 190(1):263-268.
4. Jelinek JS, Kransdorf MJ, Shmookler BM, et al. Liposarcoma of the extremities: MR and CT imaging findings in the histologic subtypes. *Radiology* 1993; 186(2):455-459.
5. Sundaram M, McGuire MH, Herbold DR. Magnetic resonance imaging of soft tissue masses: an evaluation of fifty-three histologically proven tumors. *Magn Reson Imaging* 1988; 6(3):237-248.
6. Sostman HD, Prescott DM, Dewhirst MW, et al. MR imaging and spectroscopy for prognostic evaluation in soft-tissue sarcomas. *Radiology* 1994; 190(1):269-275.

An ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

7. Adler RS, Bell DS, Bamber JC, et al. Evaluation of soft tissue masses using segmented color Doppler velocity images: preliminary observations. *AJR* 1999; 172(3):781-788.
8. Griffith JF, Chan DPN, Kumta SM, et al. Does Doppler analysis of musculoskeletal soft-tissue tumours help predict tumour malignancy? *Clin Radiol* 2004; 59(4):369-375.
9. Inampudi P, Jacobson JA, Fessell DP, et al. Soft-tissue lipomas: accuracy of sonography in diagnosis with pathologic correlation. *Radiology* 2004; 233(3):763-767.
10. Cohen EK, Kressel HY, Perosio T, et al. MR imaging of soft-tissue hemangiomas: correlation with pathologic findings. *AJR* 1988; 150(5):1079-1081.
11. Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant neoplasms: report of the Radiology Diagnostic Oncology Group. *Radiology* 1997; 202(1):237-246.
12. De Schepper AM, Ramon FA, Degryse HR. Magnetic resonance imaging of soft tissue tumors. *J Belge Radiol* 1992; 75(4):286-296.
13. Crim JR, Seeger LL, Yao L, et al. Diagnosis of soft-tissue masses with MR imaging: can benign masses be differentiated from malignant ones? *Radiology* 1992; 185(2):581-586.
14. Jones BC, Sundaram M, Kransdorf MJ. Synovial sarcoma: MR imaging findings in 34 patients. *AJR* 1993; 161(4):827-830.
15. White LM, Wunder JS, Bell RS, et al. Histologic assessment of peritumoral edema in soft tissue sarcoma. *Int J Radiat Oncol Biol Phys* 2005; 61(5):1439-1445.
16. Gielen JL, DeSchepper AM, Vanhoenacker F, et al. Accuracy of MRI in characterization of soft tissue tumors and tumor-like lesions. A prospective study in 548 patients. *Eur Radiol* 2004; 14(12):2320-2330.
17. Moulton JS, Blebea JS, Dunco DM, et al. MR imaging of soft-tissue masses: diagnostic efficacy and value of distinguishing between benign and malignant lesions. *AJR* 1995; 164(5):1191-1199.
18. Teo EL, Strouse PJ, Hernandez RJ. MR imaging differentiation of soft-tissue hemangiomas from malignant soft-tissue masses. *AJR* 2000; 174(6):1623-1628.
19. Panzarella MJ, Naqvi AH, Cohen HE, Damron TA. Predictive value of gadolinium enhancement in differentiating ALT/WD liposarcomas from benign fatty tumors. *Skeletal Radiol* 2005; 34(5):272-278.
20. van der Woude HJ, Verstraete KL, Hogendoorn PC, et al. Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? *Radiology* 1998; 208(3):821-828.
21. van Rijswijk CSP, Geirnaerd MJA, Hogendoorn PC, et al. Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy. *Radiology* 2004; 233(2):493-502.
22. Wang CK, Li CW, Hsieh TJ, et al. Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results. *Radiology* 2004; 232(2):599-605.
23. van Rijswijk CSP, Kunz P, Hogendoorn PCW, et al. Diffusion-weighted MRI in the characterization of soft-tissue tumors. *J Magn Reson Imaging* 2002; 15(3):302-307.
24. Dewhirst MW, Sostman HD, Leopold KA, et al. Soft-tissue sarcomas: MR imaging and MR spectroscopy for prognosis and therapy monitoring: work in progress. *Radiology* 1990; 174(3):847-853.

An ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.